(Q39455555)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

title

Novel insights into mesothelioma biology and implications for therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Timothy A Yap

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Joachim G Aerts

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Dean A Fennell

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

language of work or name

English

0 references

publication date

1 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

475-488

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc.2017.42

26 March 2020

exact match

0 references

cites work

Malignant Mesothelioma: Global Incidence and Relationship with Asbestos

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Malignant mesothelioma: facts, myths, and hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Continuing increase in mesothelioma mortality in Britain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Pathology of malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Evaluation of clonal origin of malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Response evaluation in mesothelioma: Beyond RECIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Tracking genomic cancer evolution for precision medicine: the lung TRACERx study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Inactivation of p16INK4a expression in malignant mesothelioma by methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

A conditional mouse model for malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Genomic events associated with progression of pleural malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Role of the INK4a locus in tumor suppression and cell mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Yin Yang 1 is a negative regulator of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Loss of the tumor suppressor BAP1 causes myeloid transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Germline BAP1 mutations predispose to malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Polycomb repressor complex-2 is a novel target for mesothelioma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Loss of BAP1 function leads to EZH2-dependent transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

LATS2 is a tumor suppressor gene of malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

A mouse model recapitulating molecular features of human mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Development of therapeutic combinations targeting major cancer signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Combining Molecularly Targeted Agents: Is More Always Better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Immuno-oncology combinations: raising the tail of the survival curve

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

From theoretical synergy to clinical supra-additive toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Discovery of mesothelin and exploiting it as a target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

A binding domain on mesothelin for CA125/MUC16

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Molecular pathogenesis of malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Tumor-associated macrophages in thoracic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Anti-CTLA-4 therapy for malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Targeting immune checkpoints: New opportunity for mesothelioma treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Global mesothelioma epidemic: Trend and features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Asbestos ban in India: challenges ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Asbestos is not just asbestos: an unrecognised health hazard

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

The Hippo pathway and human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Checkpoint Blockade in Lung Cancer and Mesothelioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Pleural mesothelioma cases in Biancavilla are related to a new fluoro-edenite fibrous amphibole

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.42

Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province

31 March 2020

1 reference

12 December 2020

Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area.

1 reference

12 December 2020

Carcinogenicity studies on fibres, metal compounds, and some other dusts in rats.

1 reference

12 December 2020

Malignant mesotheliomas in a small village in the Anatolian region of Turkey: an epidemiologic study

1 reference

12 December 2020

Codeletion of p15 and p16 in primary malignant mesothelioma

1 reference

12 December 2020

Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.

1 reference

12 December 2020

Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma

1 reference

12 December 2020

Germline mutations in BAP1 impair its function in DNA double-strand break repair

1 reference

12 December 2020

p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma

1 reference

12 December 2020

Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.

1 reference

12 December 2020

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

1 reference

12 December 2020

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart

1 reference

12 December 2020

Mortality from lung cancer in asbestos workers

1 reference

12 December 2020

Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide

1 reference

12 December 2020

ASBESTOS EXPOSURE AND NEOPLASIA.

1 reference

12 December 2020

Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42

1 reference

12 December 2020

Immunotherapy prospects in the treatment of lung cancer and mesothelioma

1 reference

12 December 2020

Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor

1 reference

12 December 2020

CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation.

1 reference

12 December 2020

Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation.

1 reference

12 December 2020

Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.

1 reference

12 December 2020

Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo

1 reference

12 December 2020

Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2017.42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28740119%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference